As we head towards the end of the year that marks Metrion’s 10th anniversary, it also marks my first year as CEO. Looking back over Metrion’s first decade, I feel immensely proud of what the company has built. Transforming world-class science into a thriving, customer-focused business is deeply rewarding. From those early days of learning how to commercialise our expertise, to becoming a trusted partner to leading pharmaceutical and biotech companies worldwide, every milestone has been achieved through the dedication and excellence of our team. Our culture of collaboration, integrity, and continuous improvement has been the foundation of our success, and it’s what continues to set Metrion apart today.
A significant milestone for Metrion this year was the launch of our NaV1.9 assays, which enable our customers to accelerate discovery of novel, non-opioid pain therapeutics with greater efficiency and confidence. NaV1.9 represents a highly valuable but technically demanding ion channel target, and the Metrion team’s delivery of a robust, high-throughput assay is a real breakthrough for the field.
The impact of the NaV1.9 campaign was recognised by the Life Science Sales and Marketing Awards for ‘Campaign of the Year’ – a reflection of the team effort across business functions, built on scientific excellence and shaped through close collaboration. Of particular note is the outstanding work of our R&D team, whose innovation, rigour and deep ion channel expertise enabled the development of our exceptional NaV1.9 assays. Their commitment laid the scientific foundation that made this campaign possible.
It’s clear that avoiding late-stage drug failure remains one of the biggest challenges facing our industry. With cardiac safety issues alone driving up to a third of clinical attrition, we’ve focused on helping our customers predict cardiac risk to protect their pipeline. By embedding our clinically translatable cardiomyocyte assay into preclinical strategies, we’re helping customers safeguard development investment, accelerate their path to key milestones, protect shareholder value, and strengthen their approach to risk management and due diligence.
Looking to the future, our focus is firmly on growth, innovation, and impact. We plan to expand our scientific capabilities, strengthen our partnerships across the global drug discovery community, and continue investing in technology and people. Ion channel science remains at the heart of everything we do, but our vision is broader - to help our customers accelerate the discovery of safer, more effective medicines through scientific excellence and operational reliability. The next decade will see Metrion deepen its global presence, and continue delivering world leading expertise and insight that enables our customers to confidently develop real-world breakthroughs for patients everywhere.
As I reflect on this remarkable year, I’d like to extend my sincere thanks to our customers for their continued trust, collaboration, and partnership. I am equally grateful to the entire Metrion team, whose dedication, expertise, and resilience have made this an exceptional year.
I, and the Metrion team, wish you a healthy and peaceful holiday season.
As we head towards the end of the year that marks Metrion’s 10th anniversary, it also marks my first year as CEO. Looking back over Metrion’s first decade, I feel immensely proud of what the company has built. Transforming world-class science into a thriving, customer-focused business is deeply rewarding. From those early days of learning how to commercialise our expertise, to becoming a trusted partner to leading pharmaceutical and biotech companies worldwide, every milestone has been achieved through the dedication and excellence of our team. Our culture of collaboration, integrity, and continuous improvement has been the foundation of our success, and it’s what continues to set Metrion apart today.
A significant milestone for Metrion this year was the launch of our NaV1.9 assays, which enable our customers to accelerate discovery of novel, non-opioid pain therapeutics with greater efficiency and confidence. NaV1.9 represents a highly valuable but technically demanding ion channel target, and the Metrion team’s delivery of a robust, high-throughput assay is a real breakthrough for the field.
The impact of the NaV1.9 campaign was recognised by the Life Science Sales and Marketing Awards for ‘Campaign of the Year’ – a reflection of the team effort across business functions, built on scientific excellence and shaped through close collaboration. Of particular note is the outstanding work of our R&D team, whose innovation, rigour and deep ion channel expertise enabled the development of our exceptional NaV1.9 assays. Their commitment laid the scientific foundation that made this campaign possible.
It’s clear that avoiding late-stage drug failure remains one of the biggest challenges facing our industry. With cardiac safety issues alone driving up to a third of clinical attrition, we’ve focused on helping our customers predict cardiac risk to protect their pipeline. By embedding our clinically translatable cardiomyocyte assay into preclinical strategies, we’re helping customers safeguard development investment, accelerate their path to key milestones, protect shareholder value, and strengthen their approach to risk management and due diligence.
Looking to the future, our focus is firmly on growth, innovation, and impact. We plan to expand our scientific capabilities, strengthen our partnerships across the global drug discovery community, and continue investing in technology and people. Ion channel science remains at the heart of everything we do, but our vision is broader - to help our customers accelerate the discovery of safer, more effective medicines through scientific excellence and operational reliability. The next decade will see Metrion deepen its global presence, and continue delivering world leading expertise and insight that enables our customers to confidently develop real-world breakthroughs for patients everywhere.
As I reflect on this remarkable year, I’d like to extend my sincere thanks to our customers for their continued trust, collaboration, and partnership. I am equally grateful to the entire Metrion team, whose dedication, expertise, and resilience have made this an exceptional year.
I, and the Metrion team, wish you a healthy and peaceful holiday season.
As we head towards the end of the year that marks Metrion’s 10th anniversary, it also marks my first year as CEO. Looking back over Metrion’s first decade, I feel immensely proud of what the company has built. Transforming world-class science into a thriving, customer-focused business is deeply rewarding. From those early days of learning how to commercialise our expertise, to becoming a trusted partner to leading pharmaceutical and biotech companies worldwide, every milestone has been achieved through the dedication and excellence of our team. Our culture of collaboration, integrity, and continuous improvement has been the foundation of our success, and it’s what continues to set Metrion apart today.
A significant milestone for Metrion this year was the launch of our NaV1.9 assays, which enable our customers to accelerate discovery of novel, non-opioid pain therapeutics with greater efficiency and confidence. NaV1.9 represents a highly valuable but technically demanding ion channel target, and the Metrion team’s delivery of a robust, high-throughput assay is a real breakthrough for the field.
The impact of the NaV1.9 campaign was recognised by the Life Science Sales and Marketing Awards for ‘Campaign of the Year’ – a reflection of the team effort across business functions, built on scientific excellence and shaped through close collaboration. Of particular note is the outstanding work of our R&D team, whose innovation, rigour and deep ion channel expertise enabled the development of our exceptional NaV1.9 assays. Their commitment laid the scientific foundation that made this campaign possible.
It’s clear that avoiding late-stage drug failure remains one of the biggest challenges facing our industry. With cardiac safety issues alone driving up to a third of clinical attrition, we’ve focused on helping our customers predict cardiac risk to protect their pipeline. By embedding our clinically translatable cardiomyocyte assay into preclinical strategies, we’re helping customers safeguard development investment, accelerate their path to key milestones, protect shareholder value, and strengthen their approach to risk management and due diligence.
Looking to the future, our focus is firmly on growth, innovation, and impact. We plan to expand our scientific capabilities, strengthen our partnerships across the global drug discovery community, and continue investing in technology and people. Ion channel science remains at the heart of everything we do, but our vision is broader - to help our customers accelerate the discovery of safer, more effective medicines through scientific excellence and operational reliability. The next decade will see Metrion deepen its global presence, and continue delivering world leading expertise and insight that enables our customers to confidently develop real-world breakthroughs for patients everywhere.
As I reflect on this remarkable year, I’d like to extend my sincere thanks to our customers for their continued trust, collaboration, and partnership. I am equally grateful to the entire Metrion team, whose dedication, expertise, and resilience have made this an exceptional year.
I, and the Metrion team, wish you a healthy and peaceful holiday season.